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In Brief Vanini et al. show that activation of preoptic GABAergic or glutamatergic neurons that regulate sleep and wakefulness does not have a substantive influence on anesthetic state transitions. The authors conclude that current correlative evidence for a mechanistic overlap of sleep and anesthesia might not have a strong causal significance.
SUMMARY
The precise mechanism of general anesthesia remains unclear. In the last two decades, there has been considerable focus on the hypothesis that anesthetics co-opt the neural mechanisms regulating sleep. This hypothesis is supported by ample correlative evidence at the level of sleep-promoting nuclei, but causal investigations of potent inhaled anesthetics have not been conducted. Here, we tested the hypothesis that chemogenetic activation of discrete neuronal subpopulations within the median preoptic nucleus (MnPO) and ventrolateral preoptic nucleus (VLPO) of the hypothalamus would modulate sleep/wake states and alter the time to loss and resumption of consciousness associated with isoflurane, a potent halogenated ether in common clinical use. We show that activating MnPO/VLPO GABAergic or glutamatergic neurons does not alter anesthetic induction or recovery time. However, activation of these neuronal subpopulations did alter sleep-wake architecture. Notably, we report the novel finding that stimulation of VLPO glutamatergic neurons causes a strong increase in wakefulness. We conclude that activation of preoptic GABAergic or glutamatergic neurons that increase sleep or wakefulness does not substantively influence anesthetic state transitions. These data indicate that the correlative evidence for a mechanistic overlap of sleep and anesthesia at the level of an individual nucleus might not necessarily have strong causal significance. INTRODUCTION General anesthetics have been in continuous clinical use for more than 170 years, but the precise mechanisms by which these drugs reversibly suppress consciousness remain unknown. Within the past two decades, there has been increased attention on the relationship between sleep and general anesthesia, with ample correlative evidence suggesting that anesthetics act by co-opting subcortical nuclei that generate sleep and wakefulness [1] [2] [3] [4] . To date, research on the mechanisms underlying the sleep-anesthesia connection has focused predominantly on the preoptic region of the hypothalamus, particularly the medial preoptic area [5] and ventrolateral preoptic nucleus (VLPO) [2, 4, [6] [7] [8] . Consistent with what has been termed the shared circuits hypothesis, putative sleep-promoting GABAergic neurons in the VLPO express cFos during the loss of consciousness induced by isoflurane, which directly activates these neurons [2] . However, despite biological plausibility and compelling correlative data, there have been no causal investigations to date that demonstrate a role for discrete neuronal subpopulations in the preoptic area of the hypothalamus in the mechanism of general anesthesia. Additionally, the median preoptic nucleus (MnPO) of the hypothalamus is critical for both sleep generation and the regulation of sleep homeostasis [9] [10] [11] [12] , but its influence on the anesthetized state remains virtually unexplored. In this study, we tested the hypothesis that activation of neuronal subpopulations within the preoptic area of the hypothalamus that promote sleep or wakefulness would modulate the entry to or exit from general anesthesia induced by isoflurane, a potent halogenated ether in common clinical use. To test this hypothesis, we used a chemogenetic approach to examine the role of GABAergic and glutamatergic neurons of both the MnPO and VLPO in anesthetic state transitions. We report that, despite altering sleep-wake states, activation of preoptic GABAergic or glutamatergic neurons had no substantive effect on the entry to or emergence from isoflurane anesthesia. These findings prompt a reconsideration of the hypothesis that general anesthesia is produced by activating nuclei in the preoptic hypothalamus known to promote or regulate sleep.
RESULTS

Activation of Neuronal Subpopulations in the Median Preoptic Nucleus Did Not Alter Anesthetic-State Transitions
To determine whether activation of GABAergic or glutamatergic neurons in the MnPO ( Figure S4 ) modulates anesthetic induction and recovery time, mice were exposed to a clinically relevant (1.5%) or a sub-anesthetic (1.2%) concentration of isoflurane for 30 min. Relative to vehicle, activation of GABAergic neurons in the MnPO (n = 17 mice) prior to exposure to 1.5% isoflurane did not alter anesthetic induction (p = 0.1256) or recovery time (p = 0.2198; Figure 1B ). Activation of glutamatergic neurons (n = 18 mice) did not change induction time (p = 0.3577); recovery time was increased (p = 0.0071) after injection of 0.5 mg/kg clozapine-N-oxide (CNO) only (p value for saline versus 1.0 mg/kg CNO > 0.9999; Figure 1C ). The statistical significance between 0.5 mg/kg CNO and vehicle was caused by a single outlier (p value without outlier = 0.2919). The estrous cycle stage was identified in all female mice after each anesthesia experiment by histological assessment of vaginal smears. Female mice were used in 78 experiments, 60% of which were conducted during diestrus, 25% during metestrus, and 15% during estrous or proestrus. Changes in the cycle stage between control versus 0.5 mg/kg CNO and control versus 1.0 mg/kg CNO were observed, respectively, in 18% and 19% of the experiments. Relative to control, there were no significant differences in induction and recovery time as a function of sex or estrous cycle stage. Similarly, activation of MnPO GABAergic and glutamatergic neurons prior to exposure to 1.2% isoflurane (a subanesthetic concentration) did not change anesthetic induction and recovery time (n = 8 Vgat-Cre mice, p = 0.5469 and 0.6406; n = 7 Vglut2-Cre mice, p = 0.6875 and 0.7813; Figures  1D and 1E ). Consistent with these behavioral findings, there was no difference in breathing rates between treatment conditions (p > 0.1) at 1.5% or 1.2% isoflurane. Mice exposed to 1.2% exhibited a few transient wake-like episodes during anesthesia, ranging from limb movements to the resumption of righting. Post hoc analysis revealed no differences in the amount of wake-like episodes between vehicle and CNO (p > 0.9999). To rule out any non-specific effect of CNO, an adverse effect from the vector injection (i.e., mechanical and/or inflammatory tissue damage), or Cre-associated toxicity [13] on anesthetic induction/recovery time, we conducted additional anesthesia experiments using the following groups of Vgat-Cre and Vglut2-Cre mice: (1) mice injected with the vector but without expression of hM3Dq receptors ( Figure S1 ; Vgat-Cre, n = 7 and Vglut2-Cre, n = 6); (2) sham operated Vgat-Cre (n = 6) and Vglut2-Cre (n = 5); and (3) naive mice (n = 5 in each mouse line; the results from both groups are shown in Figure S2 ). Relative to vehicle, 1.0 mg/kg CNO administration did not alter anesthetic state transitions in any of the three control groups.
Activation of Neuronal Subpopulations in the Median
Preoptic Nucleus Altered Sleep-Wake Architecture and Reduced Core Body Temperature In a second set of experiments, we tested whether selective activation of MnPO GABAergic and glutamatergic neurons (during the same time period during which the anesthesia experiments were conducted) modulates sleep-wake architecture (n = 6 Vgat-Cre and n = 7 Vglut2-Cre mice). Figure 2 shows representative examples of electrophysiological recordings during wakefulness, non-rapid eye movement (NREM) sleep, and rapid eye movement (REM) sleep ( Figure 2B ) and sleep-wake patterns with their p = 0.0313) and decreased REM sleep (p = 0.0156); total time in wakefulness was not significantly different (p = 0.0781). CNO caused a significant reduction in the number of wakefulness (p = 0.0156), NREM sleep (p = 0.0156), and REM sleep (p = 0.0313) bouts and an increase in NREM bout duration (p = 0.0156; e.g., more consolidated sleep). Activation of MnPO glutamatergic neurons decreased REM sleep (p = 0.0391) but did not alter wakefulness and NREM sleep (p = 0.3438 and 0.5000, respectively). The decrease in REM sleep (695.70 s ± 71.95 versus 382.12 s ± 72.21) is at the expense of non-significant increases in the time spent in wakefulness (3,956 s ± 584.70 versus 4,199 s ± 434; p = 0.3804) and NREM sleep (6,148 s ± 534.50 versus 6,219 s ± 423.50; p = 0.4596). To control for potential adverse effects of the vector injection and non-specific effects of 1.0 mg/kg CNO on sleep-wake architecture, additional studies were conducted in sham Vgat-Cre (n = 5) and Vglut2-Cre (n = 5) mice. Duration of wakefulness, NREM sleep, and REM sleep were not different in sham versus transfected mice, and CNO administration to sham mice did not alter the duration of sleep and wakefulness states ( Figure S3 ).
Given the recently identified role of MnPO glutamatergic neurons in regulating both temperature and sleep [9, 10] , changes in body temperature were assessed in a subset of awake mice before and during 90 min after 1.0 mg/kg CNO administration. As expected [10] , CNO administration to Vglut2-Cre mice (n = 9) induced a sustained reduction in body temperature (treatment effect; F(1, 170) = 65.41; p < 0.0001), although there was no temperature change in Vgat-Cre mice (n = 10; Figure 3 ). There was no significant correlation between the number of mCherry-positive glutamatergic neurons and the magnitude of temperature change. In both mouse lines, CNO administration (1.0 mg/kg) significantly increased cFos expression in MnPO hM3Dq-positive neurons (p < 0.0001 in Vgat-Cre and p = 0.0002 in Vglut2-Cre mice; Figure 4 ). Together, these data indicate that activation of MnPO GABAergic and glutamatergic neurons results in the expected changes of promoting sleep and reducing temperature but does not alter anesthetic state transitions.
Activation of Neuronal Subpopulations in the Ventrolateral Preoptic Nucleus Did Not Alter Anesthetic-State Transitions
The expression pattern of hM3Dq designer receptors in this study ( Figure S5) is consistent with what has been termed the extended VLPO [14, 15] , but we will hereafter refer to it as VLPO. Given the unexpected finding that selective manipulation of two neuronal subpopulations within the MnPO did not modulate the entry to and exit from the anesthetized state, we conducted the same experiments in VLPO, a hypothalamic nucleus that is critical for the generation of NREM sleep, as a control site [15] . Figure 5 shows that activation of GABAergic or glutamatergic neurons in the VLPO, prior to exposure to 1.5% (n = 10 Vgat-Cre and n = 6 Vglut2-Cre mice) or 1.2% (n = 4 Vgat-Cre and n = 4 Vglut2-Cre mice) isoflurane, did not alter anesthetic induction or recovery time.
Activation of Neuronal Subpopulations in the Ventrolateral Preoptic Nucleus Altered Sleep-Wake Architecture
Following anesthesia experiments, we conducted sleep studies to determine whether similar conditions of activated GABAergic and glutamatergic VLPO neurons play a role in sleep-wake control. These sleep studies were conducted during the same time period (i.e., 3 h spanning CNO/vehicle injection to emergence) as the anesthesia experiments. Representative examples of the electrophysiological signatures of wake, NREM sleep, and REM sleep in Vglut2-Cre mice are shown in Figure 6B . The temporal organization of sleep-wake states and changes in power spectral density after vehicle or 1.0 mg/kg CNO administration are depicted in Figures 6C and 6D , respectively. Group data plotted in Figures 6E-6G demonstrate that activation of glutamatergic neurons in the VLPO (n = 4 mice) increases the time in wakefulness (p = 0.0233; 79% increase) and reduces NREM sleep (p = 0.0351) and REM sleep (p = 0.0176). There were no significant changes in the number of bouts or bout duration in any of the three states. Chemogenetic stimulation of GABAergic neurons in the VLPO (n = 4 mice) did not alter sleep-wake architecture (p > 0.1000 for wakefulness, NREM, and REM sleep). Collectively, activation of GABAergic or glutamatergic neurons in the VLPO does not alter state transitions induced by isoflurane, despite a robust alteration of sleepwake architecture induced by activation of glutamatergic subpopulations.
DISCUSSION
These data show that chemogenetic stimulation of GABAergic or glutamatergic neurons in the MnPO and VLPO does not substantially alter state transitions related to isoflurane anesthesia. To our knowledge, this is the first direct assessment of a causal role for two major sleep-promoting nuclei [9, 10, 15] , to the resolution of a single-cell subtype, in the mechanisms of inhaled general anesthesia. Our results are highly relevant-and rather unexpectedbecause a prevailing hypothesis in the field posits that general anesthetics produce the loss of consciousness by co-opting nuclei that regulate sleep-wake states [1, 2, 16] . This hypothesis has been supported by abundant correlative evidence suggesting that the preoptic region of the hypothalamus, particularly the medial preoptic area [5] and VLPO [2, 4, [6] [7] [8] , plays a key role in the relationship between sleep and anesthesia. Consistent with the shared circuits hypothesis, previous work using cFos-dependent tagging and selective stimulation of previously active (tagged) neurons showed that sedation with dexmedetomidine and NREM sleep are produced, in part, by the same neuronal array within the preoptic area [17] . Preoptic galanin neurons mediate, in part, sleep homeostasis as well as the sedative and hypothermic effect of dexmedetomidine [18] . However, dexmedetomidine is clinically used in humans as a sedative, and its hypnotic, NREM-sleep-like effect is readily reversible upon stimulation, unlike general anesthesia with isoflurane, a halogenated ether used at clinically relevant concentrations in the current study.
Importantly, our study shows that activation of GABAergic and glutamatergic neurons in the MnPO and VLPO altered sleep-wake architecture during a similar time period in which anesthesia experiments were conducted. Consistent with previously published work [9, 10] , activation of GABAergic neurons in the MnPO increased the amount of NREM sleep. Another remarkable finding was that activation of glutamatergic neurons in the VLPO caused a strong increase in wakefulness and a reduction in both NREM and REM sleep. These data are novel because no previous studies have examined the role of VLPO [11, 17, 19] . The modulation of sleep and wakefulness caused by stimulation of preoptic neurons is of relevance to our study because of the well-known relationship between sleep homeostasis and anesthesia. For example, sleep deprivation or sleep loss caused by chronic VLPO lesions potentiates the hypnotic effect of propofol and the inhalational anesthetic sevoflurane [6, 20, 21] . Additionally, general anesthesia has been shown to satisfy the homeostatic sleep drive in a drug-specific manner [21] [22] [23] . Thus, the dual role of these preoptic neurons in sleep generation and the regulation of sleep homeostasis strengthened our prediction that stimulation of preoptic sleep-or wake-promoting neurons would alter anesthetic induction and recovery time. Contrary to our prediction, activation of preoptic neurons that increase sleep or wakefulness did not affect anesthetic state transitions. An interesting possibility that remains to be explored is whether increasing the time between CNO injection and behavioral testing, allowing more time for the sleep/wake drive to accrue, or varying the circadian time of the experiment (i.e., early morning versus evening) would yield a different outcome. It is also important to consider other subcortical nodes that are not classically considered critical for sleep regulation but might play a more relevant role in general anesthetic mechanisms. For example, recent and noteworthy studies showed that glutamatergic neurons in the lateral habenula facilitate the hypnotic effect of the intravenous anesthetic propofol [24] , and neuroendocrine cells within the supraoptic nucleus promote NREM sleep and facilitate general anesthesia [25] . These studies, in conjunction with our complementary findings, should prompt the field to consider exploring additional brain regions and nuclei beyond those classically known to regulate sleep and wakefulness. Furthermore, it is becoming increasingly evident that widespread neural networks encompassing multiple nuclei within the rostral hypothalamus orchestrate the features of complex behaviors and states, such as sleep, sedation, and anesthesia [10, 11, 17, 18, 26, 27 ]. An unexpected finding was that activation of glutamatergic neurons in the MnPO reduced REM sleep and did not alter NREM sleep. Harding et al. [10] recently demonstrated that sleep generation and the reduction of body temperature are controlled by the same subset of glutamatergic neurons (Vglut2 and nNOS1) localized within the MnPO and the medial preoptic area. This is important because we show that activation of glutamatergic neurons in the MnPO caused a sustained decrease in body temperature, indicating that we activated at least a proportion of the glutamatergic cells that also promote sleep. Contrasting our results with those obtained in control mice, it seems unlikely that tissue damage caused by the injection procedure or the vector itself [13] selectively lesioned the sleep-promoting cells, sparing a neuronal group that causes hypothermia. The fact that VLPO GABAergic neurons did not increase sleep during the light period is not inconsistent with prior studies. GABAergic neurons in the VLPO that co-express galanin project to (among other major wakepromoting centers) the tuberomammillary nucleus of the hypothalamus [28] . Optogenetic and chemogenetic stimulation of VLPO GABAergic/galaninergic neurons increases NREM sleep, but chemogenetic activation during the light period only produces a modest increase [15] . An evident limitation of our study is that our approach did not allow us to assess different subpopulations of VLPO GABAergic cells by targeting, for example, projection-specific or galanin-positive neurons. However, the discrepancy between our findings and the evidence reviewed above may also be attributable to the vast neurochemical and functional diversity of both GABAergic and glutamatergic neurons in the preoptic area [9, 10, 29] . It is important to note that the reduction of body temperature in Vglut2-Cre mice, as well as the changes in sleep architecture and Fos expression in both Vgat-Cre and Vglut2-Cre mice, provided functional validation of hM3Dq receptors in the MnPO and VLPO. Current Biology 30, 1-9, March 9, 2020 5
Collectively, our data suggest that activation of preoptic GABAergic or glutamatergic neurons that increase sleep or wakefulness does not substantially influence anesthetic state transitions. These data also suggest that the correlative evidence for a mechanistic overlap of sleep and anesthesia at the level of an individual nucleus, or even individual cell subtypes, might not necessarily have strong causal significance. The present study is limited in its restriction to one anesthetic and only used neuronal stimulation techniques, but the findings bring into question the long-standing hypothesis in the field that activation of individual nuclei associated with the promotion of sleep is a major contributor to the mechanism of general anesthesia. Furthermore, given the strong biological plausibility and correlative evidence supporting the shared circuits hypothesis, these data also suggest that the systems neuroscience of general anesthesia requires causal investigations and cannot rely upon a priori or theoretical bases regarding the circuits mediating anesthetic-induced unconsciousness.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
STAR+METHODS KEY RESOURCES TABLE LEAD CONTACT AND MATERIALS AVAILABILITY
This study did not generate any new unique materials. Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Giancarlo Vanini (gvanini@umich.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
All procedures using animals were approved by the Institutional Animal Care and Use Committee, the Institutional Biosafety Committee, and were conducted following recommendations from the Guide for the Care and Use of Laboratory Animals. We studied adult Vgat-IRES-Cre: Slc32a1 tm2(cre)Lowl/ J (JAXÒ mice, Stock # 016962) [9, 10, [30] [31] [32] [33] , and Vglut2-IRES-Cre: Slc17a6 tm2(cre)Lowl/ J (JAXÒ mice, Stock # 016963) [31] [32] [33] [34] [35] mice (16-20 weeks old, weighing 18 -25 g at the time of surgery; 27 male, 26 female Vgat-Cre and 32 male, 22 female Vglut2-Cre). Mice were bred at the institutional breeding colony facility and housed in a 12-h light:dark cycle with unrestricted access to food and water. All mice were genotyped (Transnetyx) before use. REAGENT Measurements of Body Temperature After Activation of GABAergic or Glutamatergic Neurons in the MnPO Temperature experiments were conducted after MnPO anesthesia and sleep experiments. Vgat-Cre and Vglut2-Cre mice were briefly and gently restrained for measurements of body temperature using a lubricated mouse rectal probe (Model# 600-1000, Barnant Company, Barrington, IL, USA). Temperature was measured before and after an intraperitoneal injection of CNO (1 mg/kg) in 10-min intervals for 90 minutes [45] . Hypothermic mice were placed back in their cages under a heating lamp between testing intervals. Changes in core body temperature after CNO administration are shown in Figure 3 .
Electroencephalographic -Electromyographic Recordings and Analysis of Sleep-Wakefulness States
Three weeks after vector injection, mice were conditioned to tethering in the recording setup for 5 days before sleep experiments began. Thereafter, mice received an intraperitoneal injection (10:00 AM) of vehicle or CNO (1.0 mg/kg), and EEG/EMG signals were recorded continuously for 3 hours -the duration of anesthesia experiments-post-injection. Monopolar EEG signals and EMG signals were recorded and digitized using a Model 1700 AC amplifier (A-M Systems, Sequim, WA, USA), a Micro3 1401 acquisition unit and Spike2 software (Cambridge Electronic Design, Cambridge, UK). Electrophysiologic signals were bandpass filtered between 0.1 -500 Hz (EEG) and 10 -500 Hz (EMG). A video recording time-synchronized with our EEG-EMG recordings was used for behavioral assessments during sleep/wake analysis. States of wakefulness, non-rapid eye movement (NREM) sleep and rapid eye movement (REM) sleep were manually scored offline in 5 s epochs using standard criteria ( Figures 2B and 6B ). Wakefulness was recognized by the presence of low-amplitude, high-frequency EEG activity, with high muscle tone and active movements. NREM sleep was identified by the presence of high-amplitude, low-frequency EEG activity with reduced muscle tone. REM sleep was recognized by low-amplitude, high-frequency EEG activity with prominent theta waveforms, along with sustained muscle atonia. The total time spent in wakefulness, NREM sleep and REM sleep was compared between treatment conditions in Cre mice expressing hM3Dq receptors (Figures 2 and 6 ) and sham-injected controls ( Figure S3 ).
Identification of Reproductive Cycle Stage
After each anesthesia experiment, female mice were briefly restrained and vaginal smear samples were collected following a published protocol [46, 47] . The unstained material was immediately observed using low-illumination light microscopy under a 10x objective (Primo Star, Carl Zeiss Microscopy, LLC, Thornwood, NY, USA). The cycle stage was identified as proestrus, estrus, metestrus and diestrus, according to standard histologic criteria [46] .
Immunohistochemistry for Localization of Vector Injection Sites (mCherry) and Assessment of CNO-induced Neuronal Activation (cFos)
For cFos/mCherry immunohistochemistry (Figure 4 ), mice received an intraperitoneal injection of vehicle or CNO (1 mg/kg) 90 minutes before euthanasia. Mice were deeply anesthetized with isoflurane, perfused transcardially with 0.1 M phosphate buffered saline pH 7.4 (PBS) followed by 5% formalin in PBS using a MasterFlex perfusion pump (Cole Palmer, Vernon Hills, IL, USA). The brains were removed and post-fixed in 5% formalin overnight at 4 C. Thereafter, brains were cryoprotected with 20% sucrose in PBS for 3 to 5 days, frozen in Tissue-Plus (Fisher Healthcare, Houston, TX, USA), and sectioned coronally at 40 mm using a cryostat (CM3050S, Leica Microsystems, Nussloch, Germany). A series of brain sections containing the MnPO were blocked in PBS containing 0.25% Triton X-100 and 3% normal goat serum (Vector Laboratories, Burlingame, CA, USA) for 60 min at room temperature. Sections were then processed for mCherry immunolabeling, or sequentially processed for double immunohistochemistry for mCherry and cFos. For mCherry, sections were incubated in primary antiserum overnight at room temperature. We used a rat monoclonal anti-mCherry (1:30000; Thermo Fisher Scientific, Cat.#: M11217). The next morning, sections were washed in PBS and incubated in a donkey anti-rat secondary antiserum (1:500; Alexa Fluor 594, Thermo Fisher Scientific, Cat.#: A-21209) for 2 h at room temperature. For cFos, sections were incubated in a rabbit polyclonal anti-cFos (1:5000; Millipore Sigma, Cat.#: ABE457) overnight at room temperature. The next morning, slices were washed in PBS and incubated in a donkey anti-rabbit secondary antiserum (1:500; Alexa Fluor 488, Thermo Fisher Scientific, Cat.#: A-21206) for 2 h at room temperature. Following incubation in the respective secondary antisera, tissues were washed in PBS, float-mounted on glass slides and coverslipped with SlowFade Diamond (S36972 or S36973; Thermo Fisher Scientific). All brain sections were examined using fluorescence microscopy (BX43, Olympus America Inc., Waltham, MA, USA). Only brains in which the expression of the designer receptor hM3Dq was localized to the MnPO or VLPO were included in the analysis (Figures S4 and S5) . A mouse brain atlas [48] was used for reference. The number mCherry-positive neurons that expressed cFos was quantified as the percentage of total neurons expressing mCherry in the MnPO (Figures 4A and 4B ).
QUANTIFICATION AND STATISTICAL ANALYSIS
Data analyses were performed using PRISM v7.0 (GraphPad Software Inc., La Jolla, CA). All data were tested for normality and reported as mean ± standard error of the mean. A P value < 0.05 was considered statistically significant. The time to loss and resumption of consciousness is reported as the time in seconds. Differences in the time to loss and resumption of consciousness in MnPOanesthesia experiments in which 3 concentrations of CNO were used (data shown in Figures 1B, 1C , and S1) were assessed by a Friedman test followed, when applicable, by a Dunn's multiple comparison test. All pairwise comparisons (i.e., vehicle versus 1.0 mg/kg CNO) of time to loss and resumption of consciousness were evaluated by a two-tailed Wilcoxon test. Changes in the time spent in wakefulness, NREM sleep and REM sleep were assessed by a one-tailed (MnPO Vgat and Vglut2, and VLPO Vgat)
